ArticleBiotechnology for biofuels and bioproducts2026
SynBio-DSP: an integrated synthetic biology platform with fed-batch fermentation and continuous downstream processing for sustainable production of thermostable cellulases.
Article in Biotechnology for biofuels and bioproducts, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundThe economic viability of enzymatic lignocellulosic biomass conversion is hindered by high production costs and energy-intensive recovery of thermostable enzymes. Traditional optimization approaches treat strain engineering, fermentation, and downstream processing as separate domains, leading to suboptimal system performance. This study aimed to develop an integrated platform that synergistically combines synthetic biology, machine learning-guided bioprocess optimization, and continuous downstream processing for sustainable cellulase production.
resultsWe engineered a Bacillus subtilis chassis with a Quorum-Lysis-Modulation (QLM) system for auto-induction of hyperthermostable cellulase CtCel9A and CRISPRi-mediated cell wall weakening. The QLM strain achieved a CtCel9A titer of 9.32 ± 0.29 IU/mL, a 3.6-fold increase over conventional methods. Fermentation was optimized using Gaussian Process Regression in high-throughput microbioreactors, yielding excellent predictive performance (R
conclusionsThe SynBio-DSP platform establishes a new paradigm for sustainable biocatalyst manufacturing by co-optimizing cellular design and process configuration. The integrated approach demonstrates that simultaneous improvements in productivity, cost, and environmental impact are achievable for scalable, economically viable biofuel enzyme production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.